📊 EDSA Key Takeaways
Is EDSA a Good Investment? Thesis Analysis
Edesa Biotech is a pre-revenue pharmaceutical company with severe profitability challenges, posting zero revenue and negative net income of $2.2M. While the company maintains a strong cash position of $12.1M and minimal debt, the deteriorating cash burn rate (-$2.1M operating cash flow) and consistent operating losses indicate the business has not yet achieved viability and faces significant execution risk.
Why Buy EDSA? Key Strengths
- Strong liquidity position with $12.1M in cash and 16.82x current ratio, providing runway for operations
- Minimal debt burden with 0.00x debt-to-equity ratio, reducing financial distress risk
- Stable stockholders' equity of $14.0M providing buffer against losses
EDSA Investment Risks to Consider
- Zero revenue generation indicates product commercialization failure or pre-launch phase with uncertain timelines
- Negative operating cash flow of -$2.1M annually with no revenue indicates unsustainable burn rate and eventual cash depletion
- Deteriorating profitability with worsening net income (-16.5% YoY) and EPS (-58.3% YoY) suggests accelerating losses
- High insider activity (10 Form 4 filings in 90 days) may indicate stock liquidation or confidence concerns
Key Metrics to Watch
- Quarterly revenue progression and pipeline advancement milestones
- Monthly cash burn rate and projected runway before insolvency
- Operating cash flow trend and path to cash flow breakeven
- R&D efficiency and clinical trial progression for pipeline assets
EDSA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 16.82x current ratio provides a solid financial cushion.
EDSA Profitability Ratios
EDSA vs Healthcare Sector
How Edesa Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is EDSA Overvalued or Undervalued?
Based on fundamental analysis, Edesa Biotech, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
EDSA Balance Sheet & Liquidity
EDSA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Edesa Biotech, Inc.'s revenue has declined by 74% over the 5-year period, indicating business contraction. The most recent EPS of $-1.93 indicates the company is currently unprofitable.
EDSA Growth Metrics (YoY)
EDSA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$1.7M | N/A |
| Q2 2021 | N/A | -$1.5M | N/A |
| Q1 2021 | N/A | -$1.1M | N/A |
| Q3 2020 | $500 | -$1.3M | N/A |
| Q2 2020 | N/A | -$455.6K | N/A |
| Q1 2020 | N/A | -$347.1K | N/A |
| Q2 2019 | N/A | -$392.3K | N/A |
| Q1 2019 | $20.5K | -$1.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EDSA Capital Allocation
EDSA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Edesa Biotech, Inc. (CIK: 0001540159)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EDSA
What is the AI rating for EDSA?
Edesa Biotech, Inc. (EDSA) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are EDSA's key strengths?
Claude: Strong liquidity position with $12.1M in cash and 16.82x current ratio, providing runway for operations. Minimal debt burden with 0.00x debt-to-equity ratio, reducing financial distress risk.
What are the risks of investing in EDSA?
Claude: Zero revenue generation indicates product commercialization failure or pre-launch phase with uncertain timelines. Negative operating cash flow of -$2.1M annually with no revenue indicates unsustainable burn rate and eventual cash depletion.
What is EDSA's revenue and growth?
Edesa Biotech, Inc. reported revenue of $0.0.
Does EDSA pay dividends?
Edesa Biotech, Inc. does not currently pay dividends.
Where can I find EDSA SEC filings?
Official SEC filings for Edesa Biotech, Inc. (CIK: 0001540159) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EDSA's EPS?
Edesa Biotech, Inc. has a diluted EPS of $-0.57.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EDSA a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Edesa Biotech, Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EDSA stock overvalued or undervalued?
Valuation metrics for EDSA: ROE of -16.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EDSA stock in 2026?
Our dual AI analysis gives Edesa Biotech, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EDSA's free cash flow?
Edesa Biotech, Inc.'s operating cash flow is $-2.1M, with capital expenditures of $0.0.
How does EDSA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -16.1% (avg: 15%), current ratio 16.82 (avg: 2).